A China DMF (Drug Master File) differs from a US DMF primarily in regulatory requirements, submission processes, and language. China’s DMF requires more detailed documentation, often in Chinese, and involves a different approval pathway. The US DMF focuses on confidentiality and supports FDA submissions, while China’s emphasizes transparency and compliance with NMPA standards.
